<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656394</url>
  </required_header>
  <id_info>
    <org_study_id>GL-1</org_study_id>
    <nct_id>NCT02656394</nct_id>
  </id_info>
  <brief_title>Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101</brief_title>
  <official_title>Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 - Proof of Concept, Safety, and Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GLIA LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GLIA LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28
      days in ameliorating adverse ocular side effects in patients under ongoing treatment with
      glaucoma medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is to assess the safety and efficacy of a new treatment for ocular surface disease
      associated with the use of glaucoma medications.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glaucoma medication ocular side effect symptoms</measure>
    <time_frame>Day 1 to 4 weeks</time_frame>
    <description>Glaucoma medication ocular side effect symptoms:
Ocular discomfort
Burning
Stinging
Conjunctival redness
Itching
Dryness
Foreign object sensation
Grittiness
Pain
Eyelid swelling
Eyelid redness
Photophobia
Excessive tearing
Crusty lids
Blurred vision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glaucoma medication ocular side effect signs</measure>
    <time_frame>Day 1 to 4 weeks</time_frame>
    <description>Glaucoma medication ocular side effect signs:
Tearscope tear film examination
Tear meniscus height (TMH)
Tear film break up time (NIKBUT)
Bulbar redness (BR)
Meibography
Conjunctival redness (hyperemia)
Blepharitis
Lid margin vessel inflammation
Punctate keratitis
Corneal staining
Conjunctival staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other signs</measure>
    <time_frame>Day 1 to 4 weeks</time_frame>
    <description>Other signs:
Visual acuity
Intraocular pressure
Artificial tear use
Glaucoma medication compliance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 1 to 4 weeks</time_frame>
    <description>Adverse events:
Visual acuity
Slit lamp biomicroscopy
Undilated fundoscopy examination
Intraocular pressure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ocular Surface Disease</condition>
  <arm_group>
    <arm_group_label>GL101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GL101 topical gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo topical gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GL101</intervention_name>
    <description>Topical Gel</description>
    <arm_group_label>GL101</arm_group_label>
    <other_name>Pro-Ocular</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo topical gel</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female of any race, at least 18 years of age at Visit 1 Screening.

          2. Has provided verbal and written informed consent.

          3. Be able and willing to follow instructions, including participation in all study
             assessments and visits.

          4. Currently being treated for glaucoma using at least two medications, and be willing to
             continue on the same regime.

          5. Suffers from at least two of the symptoms in the GLIA™ Glaucoma Medication Ocular Side
             Effect Symptoms Questionnaire at a severity of 2 (moderate) or more.

          6. If a woman of childbearing potential, have a negative urine pregnancy test at Visit 1
             and be using an adequate method of birth control throughout the study period.

        Exclusion Criteria:

          1. Comorbidity with other severe or chronic eye conditions that in the judgment of the
             investigator will interfere with study assessments, such as corneal opacities and
             scars, dystrophies, epithelial scarring, infections, blood clots, etc.

          2. Best corrected visual acuity (BCVA) at baseline &lt;20/200.

          3. Has a condition or history that, in the opinion of the investigator, may interfere
             significantly with the subject's participation in the study.

          4. A woman who is pregnant, nursing an infant, or planning a pregnancy.

          5. Has a known adverse reaction and/or sensitivity to the study drug or its components.

          6. Routine use (more than twice a week) of a chlorinated swimming pool.

          7. Unwilling or unable to cease using the following medications during the study period:
             Topical ocular cyclosporine (e.g. Restasis®), anti-histamines, antipsychotics, or eye
             gels.

          8. Currently enrolled in an investigational drug or device study or have used an
             investigational drug or device within 30 days prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ritch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Eye &amp; Ear Infirmary of Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Silva, MD</last_name>
    <phone>212-477-7540</phone>
    <phone_ext>5371</phone_ext>
    <email>cifgof.glaucoma@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa Alvarado</last_name>
    <phone>212-477-7540</phone>
    <phone_ext>5371</phone_ext>
    <email>vaeyeresearch@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Eye &amp; Ear Infirmary of Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Silva, MD</last_name>
      <phone>212-477-7540</phone>
      <phone_ext>5371</phone_ext>
      <email>cigof.glaucoma@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Alvarado</last_name>
      <phone>212-477-7540</phone>
      <phone_ext>5371</phone_ext>
      <email>vaeyeresearch@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Ritch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ocular surface disease</keyword>
  <keyword>glaucoma medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

